Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Anthrax Vaccine Trial Of 1,500 Patients Could Begin In Summer 2000

Executive Summary

An anthrax vaccine study involving 1,500 patients could begin as early as this summer.

You may also be interested in...

Vaccine Tax Credit In Clinton Budget Is Based On Sales To Nonprofit Groups

President Clinton's tax credit to encourage the development of vaccines for targeted diseases would be based on sales to nonprofit organizations rather than the amount spent on research and development.

DoD Investigational Drug Testing Policy Expected By Early Next Year

The Department of Defense will develop a protocol on the use of investigational drugs on military personnel that will incorporate the President's executive order and FDA's interim rule on seeking informed consent waivers. The protocol is expected by early next year.

Anthrax Vaccine Product May Be Studied By DoD; Facility Being Renovated

A longitudinal cohort study to determine the efficacy of Lansing, Michigan-based Bioport's anthrax vaccine adsorbed would be conducted under a proposal by Army Surgeon General Ronald Blank.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts